EGFR and non-small cell lung carcinoma: Targeted therapy offers a more promising outcome in advanced non-small cell lung cancer (NSCLC) [2–4], but only patients who harbor driving mutations such as epidermal growth factor receptor (EGFR) potentially benefit [5, 6].